Antidepressant Drugs Market By Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others); By Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) And Region – Global Analysis Of Market Size, Share & Trends For 2019–2020 And Forecasts To 2030
[ 176 + Pages Research Report ]Antidepressant Drugs Market to surpass USD 33.5 billion by 2030 from USD 18.40 billion in 2021 at a CAGR of 6.16% in the coming years, i.e., 2021-31
Product Overview
Depression impacts a person's thoughts, behavior, feelings, and sense of rationality. Depression drugs function by fixing chemical imbalances such as the absence of serotonin in the brain. Antidepressants assist in the treatment of depression by upholding the balance of several hormones and chemicals in the brain.
Market Highlights
Global Antidepressant Drugs Market is expected to project a notable CAGR of 6.16% in 2031.
Global Antidepressant Drugs market to surpass USD 33.5 billion by 2030 from USD 18.40 billion in 2021 at a CAGR of 6.16% in the coming years, i.e., 2021-31. An increase in the occurrence of depression, an upsurge in the geriatric population, and the arrival of novel techniques for the development of drugs with fewer side effects boost the market. Additionally, a rise in awareness regarding the disease condition and required clinical needs, and rise in number of people suffering from stress can boost the growth of the antidepressant drugs.
Global Antidepressant Drugs Market: Segments
Major Depressive Disorder to grow with the highest CAGR during 2021-31
Global Antidepressant Drugs Market is segmented by Depressive Disorder into Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others. Major depressive disorder is the maximum contributor toward the market growth as majority of the population are usually diagnosed with this disorder owing to increase in stress levels.
Selective Serotonin Reuptake Inhibitors segment to grow with the highest CAGR during 20201-31
Global Antidepressant Drugs market is divided by Product into Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others. Selective Serotonin Reuptake Inhibitors is the dominant segment due to the presence of large number of these drugs.
Market Dynamics
Drivers
Rising cases of depression
The market is primarily fueled by the rising cases of depression, increasing awareness about depression, and the rise of novel biologics. The sum of people falling prey to depression and related disorders is anticipated to continue to increase, as a result of improper eating habits, stressful work schedule, growing isolation from family and loved ones owing to technology, and the inability to adapt to the rapid pace, at which, the world is moving forward.
Increase in awareness
Increase in awareness about the disease growth and increase in the number of people suffering from stress can boost the growth of the antidepressant drugs market.
Restraint
Poor efficiency and safety profiles
Poor efficiency and safety profiles of the drug, preference for non-pharmacological therapies, and rise in amount of patent expiration of antidepressants that lead to weak pipeline are anticipated to hinder the market growth.
Global Antidepressant Drugs Market: Key Players
Allergan PLC
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
AstraZeneca
Eli Lilly and Company
GlaxoSmithKline PLC
H. Lundbeck AS
Johnson & Johnson
Pfizer Inc.
Merck & Co. Inc.
Sanofi
Sun Pharmaceuticals Pvt Ltd
Alkermes
Bristol Myers Squibb Company
Teva Pharmaceutical Industries
Eli Lilly and Co.
Takeda Pharmaceutical Co. Ltd
Forest laboratories
Akeda Pharmaceutical
Other Prominent Players
Global Antidepressant Drugs Market: Regions
Global Antidepressant Drugs Market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, Asia Pacific and the Middle East, and Africa. The Global Antidepressant Drugs market in North America held the largest market share of XX% in the year 2020.
Global Antidepressant Drugs market is further segmented by region into:
North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
Global Antidepressant Drugs market report also contains analysis on:
Antidepressant Drugs market Segments
By Depressive Disorder
Major Depressive Disorder
Obsessive-Compulsive Disorder
Generalized Anxiety Disorder
Panic Disorder
Others
By Product
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin-Norepinephrine Reuptake Inhibitors
Monoamine Oxidase Inhibitors
Serotonin Antagonist and Reuptake Inhibitors
Others
Antidepressant Drugs market Dynamics
Antidepressant Drugs market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
Antidepressant Drugs Market Report Scope and Segmentation
Report Attribute Details
Market size value in 2021 USD 18.40 billion
Revenue forecast in 2031 USD 33.5 billion
Growth Rate CAGR of 6.16% from 2021 to 2031
Base year for estimation 2020
Quantitative units Revenue in USD million and CAGR from 2021 to 2031
Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered Depressive Disorder, Product and Region
Regional scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa (MEA)
Key companies profiled Allergan PLC, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson &, Johnson, Pfizer Inc., Merck & Co. Inc., Sanofi, Sun, Pharmaceuticals Pvt Ltd, Alkermes, Bristol Myers Squibb Company, Teva Pharmaceutical Industries, Eli Lilly and Co., Takeda Pharmaceutical Co. Ltd, Forest laboratories, Akeda Pharmaceutical Other Prominent Players.
Product Overview
Depression impacts a person's thoughts, behavior, feelings, and sense of rationality. Depression drugs function by fixing chemical imbalances such as the absence of serotonin in the brain. Antidepressants assist in the treatment of depression by upholding the balance of several hormones and chemicals in the brain.
Market Highlights
Global Antidepressant Drugs Market is expected to project a notable CAGR of 6.16% in 2031.
Global Antidepressant Drugs market to surpass USD 33.5 billion by 2030 from USD 18.40 billion in 2021 at a CAGR of 6.16% in the coming years, i.e., 2021-31. An increase in the occurrence of depression, an upsurge in the geriatric population, and the arrival of novel techniques for the development of drugs with fewer side effects boost the market. Additionally, a rise in awareness regarding the disease condition and required clinical needs, and rise in number of people suffering from stress can boost the growth of the antidepressant drugs.
Global Antidepressant Drugs Market: Segments
Major Depressive Disorder to grow with the highest CAGR during 2021-31
Global Antidepressant Drugs Market is segmented by Depressive Disorder into Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others. Major depressive disorder is the maximum contributor toward the market growth as majority of the population are usually diagnosed with this disorder owing to increase in stress levels.
Selective Serotonin Reuptake Inhibitors segment to grow with the highest CAGR during 20201-31
Global Antidepressant Drugs market is divided by Product into Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others. Selective Serotonin Reuptake Inhibitors is the dominant segment due to the presence of large number of these drugs.
Market Dynamics
Drivers
Rising cases of depression
The market is primarily fueled by the rising cases of depression, increasing awareness about depression, and the rise of novel biologics. The sum of people falling prey to depression and related disorders is anticipated to continue to increase, as a result of improper eating habits, stressful work schedule, growing isolation from family and loved ones owing to technology, and the inability to adapt to the rapid pace, at which, the world is moving forward.
Increase in awareness
Increase in awareness about the disease growth and increase in the number of people suffering from stress can boost the growth of the antidepressant drugs market.
Restraint
Poor efficiency and safety profiles
Poor efficiency and safety profiles of the drug, preference for non-pharmacological therapies, and rise in amount of patent expiration of antidepressants that lead to weak pipeline are anticipated to hinder the market growth.
Global Antidepressant Drugs Market: Key Players
Allergan PLC
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
AstraZeneca
Eli Lilly and Company
GlaxoSmithKline PLC
H. Lundbeck AS
Johnson & Johnson
Pfizer Inc.
Merck & Co. Inc.
Sanofi
Sun Pharmaceuticals Pvt Ltd
Alkermes
Bristol Myers Squibb Company
Teva Pharmaceutical Industries
Eli Lilly and Co.
Takeda Pharmaceutical Co. Ltd
Forest laboratories
Akeda Pharmaceutical
Other Prominent Players
Global Antidepressant Drugs Market: Regions
Global Antidepressant Drugs Market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, Asia Pacific and the Middle East, and Africa. The Global Antidepressant Drugs market in North America held the largest market share of XX% in the year 2020.
Global Antidepressant Drugs market is further segmented by region into:
North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
Global Antidepressant Drugs market report also contains analysis on:
Antidepressant Drugs market Segments
By Depressive Disorder
Major Depressive Disorder
Obsessive-Compulsive Disorder
Generalized Anxiety Disorder
Panic Disorder
Others
By Product
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin-Norepinephrine Reuptake Inhibitors
Monoamine Oxidase Inhibitors
Serotonin Antagonist and Reuptake Inhibitors
Others
Antidepressant Drugs market Dynamics
Antidepressant Drugs market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
Antidepressant Drugs Market Report Scope and Segmentation
Report Attribute Details
Market size value in 2021 USD 18.40 billion
Revenue forecast in 2031 USD 33.5 billion
Growth Rate CAGR of 6.16% from 2021 to 2031
Base year for estimation 2020
Quantitative units Revenue in USD million and CAGR from 2021 to 2031
Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered Depressive Disorder, Product and Region
Regional scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa (MEA)
Key companies profiled Allergan PLC, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson &, Johnson, Pfizer Inc., Merck & Co. Inc., Sanofi, Sun, Pharmaceuticals Pvt Ltd, Alkermes, Bristol Myers Squibb Company, Teva Pharmaceutical Industries, Eli Lilly and Co., Takeda Pharmaceutical Co. Ltd, Forest laboratories, Akeda Pharmaceutical Other Prominent Players.
1. EXECUTIVE SUMMARY
2. GLOBAL ANTIDEPRESSANT DRUGS MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. GLOBAL ANTIDEPRESSANT DRUGS MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. GLOBAL ANTIDEPRESSANT DRUGS MARKET
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. GLOBAL ANTIDEPRESSANT DRUGS MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. BY DEPRESSIVE DISORDER: MARKET SHARE (2020-2030F)
13.1. Major Depressive Disorder, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.2. Obsessive-Compulsive Disorder, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.3. Generalized Anxiety Disorder, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.4. Cross Traffic Alert, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.5. Panic Disorder, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.6. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14. BY PRODUCTS: MARKET SHARE (2020-2030F)
14.1. Tricyclic Antidepressants, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14.2. Selective Serotonin Reuptake Inhibitors, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14.3. Serotonin-Norepinephrine Reuptake Inhibitors, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14.4. Monoamine Oxidase Inhibitors, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14.5. Serotonin Antagonist and Reuptake Inhibitors, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14.6. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
1. COMPANY PROFILE
1. ALLERGAN PLC
1. COMPANY OVERVIEW
2. COMPANY TOTAL REVENUE (FINANCIALS)
3. MARKET POTENTIAL
4. GLOBAL PRESENCE
5. KEY PERFORMANCE INDICATORS
6. SWOT ANALYSIS
7. PRODUCT LAUNCH
2. ASTRAZENECA
3. ELI LILLY AND COMPANY
4. GLAXOSMITHKLINE PLC
5. H. LUNDBECK AS
6. JOHNSON & JOHNSON
7. PFIZER INC.
8. MERCK & CO. INC.
9. SANOFI
10. SUN PHARMACEUTICALS PVT LTD
11. ALKERMES
12. BRISTOL MYERS SQUIBB COMPANY
13. TEVA PHARMACEUTICAL INDUSTRIES
14. ELI LILLY AND CO.
15. TAKEDA PHARMACEUTICAL CO. LTD
16. FOREST LABORATORIES
17. AKEDA PHARMACEUTICAL
18. OTHER PROMINENT PLAYERS
Consultant Recommendation
The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
2. GLOBAL ANTIDEPRESSANT DRUGS MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. GLOBAL ANTIDEPRESSANT DRUGS MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. GLOBAL ANTIDEPRESSANT DRUGS MARKET
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. GLOBAL ANTIDEPRESSANT DRUGS MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. BY DEPRESSIVE DISORDER: MARKET SHARE (2020-2030F)
13.1. Major Depressive Disorder, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.2. Obsessive-Compulsive Disorder, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.3. Generalized Anxiety Disorder, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.4. Cross Traffic Alert, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.5. Panic Disorder, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13.6. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14. BY PRODUCTS: MARKET SHARE (2020-2030F)
14.1. Tricyclic Antidepressants, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14.2. Selective Serotonin Reuptake Inhibitors, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14.3. Serotonin-Norepinephrine Reuptake Inhibitors, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14.4. Monoamine Oxidase Inhibitors, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14.5. Serotonin Antagonist and Reuptake Inhibitors, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
14.6. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
1. COMPANY PROFILE
1. ALLERGAN PLC
1. COMPANY OVERVIEW
2. COMPANY TOTAL REVENUE (FINANCIALS)
3. MARKET POTENTIAL
4. GLOBAL PRESENCE
5. KEY PERFORMANCE INDICATORS
6. SWOT ANALYSIS
7. PRODUCT LAUNCH
2. ASTRAZENECA
3. ELI LILLY AND COMPANY
4. GLAXOSMITHKLINE PLC
5. H. LUNDBECK AS
6. JOHNSON & JOHNSON
7. PFIZER INC.
8. MERCK & CO. INC.
9. SANOFI
10. SUN PHARMACEUTICALS PVT LTD
11. ALKERMES
12. BRISTOL MYERS SQUIBB COMPANY
13. TEVA PHARMACEUTICAL INDUSTRIES
14. ELI LILLY AND CO.
15. TAKEDA PHARMACEUTICAL CO. LTD
16. FOREST LABORATORIES
17. AKEDA PHARMACEUTICAL
18. OTHER PROMINENT PLAYERS
Consultant Recommendation
The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
